Advertisement
Advertisement

CHRS

CHRS logo

Coherus BioSciences, Inc.

1.15
USD
+0.07
+7.01%
Feb 24, 15:59 UTC -5
Closed
exchange

Pre-Market

1.15

+0.08
+7.48%

Coherus BioSciences, Inc. Profile

About

Coherus Biosciences, Inc. is a biologics platform company developing biosimilar therapeutics. Its clinical stage pipeline consists of CHS-0214 in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420 that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701 which has completed a Phase I study for the treatment of breast cancer patients. Coherus Biosciences, Inc. is headquartered in Redwood City, California.

Info & Links

CEO

Dennis M. Lanfear

Headquarters

333 TWIN DOLPHIN DRIVE, SUITE 600
REDWOOD CITY, CA 94065, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.coherus.com

Auditor

Ernst & Young LLP

Share holders

85

Employees

306

Coherus BioSciences, Inc. Statistics

Valuation Measures

Market Capitalization2

132.50M

Enterprise Value

299.31M

Enterprise Value/EBITDA(ttm)

-2.25

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

0.42

Price to Book(mrq)

--

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

47.44%

Operating Margin(ttm)

-51.65%

Profit Margin(ttm)

2.85%

Return on Equity(ttm)

--

Return on Invested Capital(ttm)

5.51%

Return on Assets(ttm)

-24.44%

Income Statement

Revenue(ttm)

304.34M

Revenue Per Share(ttm)

2.64

Gross Profit(ttm)

136.08M

EBITDA(ttm)3

-133.02M

Net Income Available to Common(ttm)

-450.00K

Diluted EPS(ttm)

-0.08

Share Statistics

Beta (5Y Monthly)

0.81

52-Week Change

-55.62%

S&P 500 52-Week Change

18.02%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

115.21M

Dividend Yield

0.00%

Float4

107.05M

% Held by Insiders

7.63%

% Held by Institutions

72.82%

Balance Sheet

Total Cash(mrq)

97.69M

Total Cash Per Share(mrq)

0.85

Total Debt(mrq)

264.51M

Total Debt/Equity(mrq)

-300.67%

Current Ratio(mrq)

1.25%

Quick Ratio(mrq)

1.09%

Book Value Per Share(mrq)

-0.76

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.43

Free Cash Flow(ytd)

-49.05M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement